|EX-31.1 - CERTIFICATION - GT Biopharma, Inc.||oxis_ex311.htm|
|EX-32.2 - CERTIFICATION - GT Biopharma, Inc.||oxis_ex322.htm|
|EX-31.2 - CERTIFICATION - GT Biopharma, Inc.||oxis_ex312.htm|
|10-Q - QUARTERLY REPORT - GT Biopharma, Inc.||oxis_10q.htm|
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Oxis International, Inc. (the “Company”), for the quarterly period ended March 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Tony Cataldo, Chief Executive Officer of the Company, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, do hereby certify, to my knowledge that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 15 U.S.C. 78m(a) or 780(d)); and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 13, 2016
/s/ Anthony Cataldo
Chief Executive Officer, Chairman, and Director
A signed original of this written statement required by Section 906 has been provided to Oxis International, Inc. and will be retained by Oxis International, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.